Challenges in the management of idiopathic pulmonary fibrosis from a low- and middle-income country

J Pak Med Assoc. 2024 Jun;74(6):1207-1209. doi: 10.47391/JPMA.9777.

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most common progressive form of interstitial lung disease (ILD) that leads to gradual deterioration of lung function and ultimately death. Data from low- and middle-income countries (LMIC) on IPF is scarce. In this communication, we report the challenges encountered in managing IPF from Pakistan's largest tertiary care centre. A total of 108 patients with IPF were evaluated at the Aga Khan University Hospital in Karachi, Pakistan from January 2017 to March 2020. A significant concern was that most patients with IPF presented late during their disease. A bigger challenge encountered in clinical practice was the cost and nonavailability of antifibrotic therapy in the country until mid-2020. Successfully addressing these limitations, it is anticipated that better care will be available for the patients suffering from IPF in this part of the world.

Keywords: Interstitial Lung Disease, Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis, LMIC..

MeSH terms

  • Aged
  • Antifibrotic Agents / therapeutic use
  • Developing Countries*
  • Female
  • Health Services Accessibility
  • Humans
  • Idiopathic Pulmonary Fibrosis* / diagnosis
  • Idiopathic Pulmonary Fibrosis* / therapy
  • Indoles
  • Lung Transplantation
  • Male
  • Middle Aged
  • Pakistan
  • Pyridones / therapeutic use

Substances

  • Antifibrotic Agents
  • Pyridones
  • nintedanib
  • pirfenidone
  • Indoles